SCHEMBL3481315

SCHEMBL3481315

Cc1ccc(Oc2nc3cc(-c4ccc5c(ccn5C)c4)c(Cl)cc3[nH]2)cc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PRKAB1 Q9Y478 16/20 1.00
PRKAG1 P54619 15/20 1.00
PRKAA2 P54646 11/20 1.00
PRKAA1 Q13131 9/20 1.00
PRKAG2 Q9UGJ0 3/20 0.73
PRKAB2 O43741 2/20 0.73
PRKAG3 Q9UGI9 2/20 0.73
TFDP2 Q14188 1/20 0.73
KDM4C Q9H3R0 1/20 0.41
CHEK2 O96017 2/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25735804 0.93 PRKAB1 (0.87) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481213 0.93 PRKAB1 (0.87) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481008 0.93 PRKAB1 (0.87) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481067 0.92 PRKAB1 (0.84) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481375 0.91 PRKAB1 (0.83) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL19876174 0.91 PRKAB1 (0.83) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL29659602 0.91 PRKAB1 (0.83) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481219 0.91 PRKAB1 (0.83) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481121 0.90 PRKAG1 (0.82) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2
SCHEMBL3481074 0.90 PRKAB1 (0.82) PRKAB1PRKAG1PRKAA2PRKAA1PRKAG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4599048-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS Trailhead Biosystems Inc. (US) 2025-08-13 EP claimed
EP-4569090-A2 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2025-06-18 EP claimed
CN-119654404-A Methods and compositions for producing oligodendrocyte progenitor cells 特雷尔赫德生物系统股份有限公司 2025-03-18 CN claimed
EP-4444870-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS Trailhead Biosystems Inc. (US) 2024-10-16 EP claimed
CN-118382694-A Methods and compositions for generating human erythroid progenitors 特雷尔赫德生物系统股份有限公司 2024-07-23 CN claimed
WO-2024063818-A9 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2024-05-23 WO claimed
WO-2024076758-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2024-04-11 WO claimed
US-20240117302-A1 COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS TRAILHEAD BIOSYSTEMS INC. 2024-04-11 US claimed
WO-2024063818-A2 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2024-03-28 WO claimed
US-20240043798-A1 METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. 2024-02-08 US claimed
US-20240034761-A1 REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS MASCARENHAS DESMOND (US) 2024-02-01 US claimed
WO-2023107477-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. (US) 2023-06-15 WO claimed
US-20230174938-A1 METHODS AND COMPOSITIONS FOR GENERATING HUMAN ERYTHROID PROGENITOR CELLS TRAILHEAD BIOSYSTEMS INC. 2023-06-08 US claimed
CN-115975911-A Use of AMPK activators to increase the efficiency of differentiation of mammalian pluripotent stem cells into definitive endoderm cells 武汉大学 2023-04-18 CN claimed
WO-2022192042-A2 REGENERATION OF MAMMALIAN TISSUES USING SYNTHETIC IMMODULINS MASCARENHAS DESMOND (US) 2022-09-15 WO claimed
EP-3723754-B1 IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
US-12610731-B2 Organic light emitting diode and organic light emitting device including the same LG DISPLAY CO., LTD. (KR) 2026-04-21 US disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 US disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 US disclosed
WO-2010025553-A1 HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 PRKAB1 5/4885PRKAG1 2/4885PRKAA2 12/4885
US-12610731-B2 Organic light emitting diode and organic light emitting device including the same SOD1, ROS1, OXA1L PRKAB1 3901/4885PRKAG1 4206/4885PRKAA2 4397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.